Trump Signs 100% Tariff on Imported Brand-Name Drugs

President Trump signed an executive order on April 3 imposing a 20% tariff on all imported brand-name pharmaceuticals, effective immediately. The tariff will escalate to 50% in 2028 and 100% by 2030 for manufacturers that have not begun "substantial onshoring" of production to US facilities, according to the order's text.

The order targets finished pharmaceutical products entering the United States from overseas manufacturing sites. Approximately 87% of active pharmaceutical ingredients used in US prescription drugs are manufactured abroad, primarily in India and China, according to the FDA's 2025 supply chain report.

"We're not going to let foreign countries hold our medicine hostage," Trump said at the signing ceremony, held at a Pfizer facility in North Carolina that the company announced would expand under the new policy. Pfizer's CEO Albert Bourla stood behind the president, though the company declined to comment on whether the expansion was contingent on the tariff order.

The pharmaceutical industry's response was immediate and divided. The Pharmaceutical Research and Manufacturers of America, the industry's largest lobby, issued a statement expressing "deep concern about potential disruptions to patient access." Teva Pharmaceutical, the world's largest generic drug maker, saw its stock fall 8% in after-hours trading. Teva manufactures most of its products in Israel and India.

Generic drugs were excluded from the order's scope, but industry analysts warned the distinction may prove unstable. "The supply chains for generics and brand-name drugs are deeply intertwined," said Stacie Dusetzina, a health policy professor at Vanderbilt University, in an interview with STAT News. "You can't tariff one without affecting the other."

Indian pharmaceutical industry leaders reacted with alarm. The Indian Pharmaceutical Alliance called the tariff "a direct threat to global medicine access" and noted that Indian manufacturers supply approximately 40% of the US generic drug market and significant volumes of brand-name contract manufacturing.

European media framed the order primarily through its trade implications. The Financial Times reported that Novo Nordisk, the Danish maker of Wegovy and Ozempic, could face tariffs on products shipped from its Denmark manufacturing sites. The company's US revenue exceeded $15 billion in 2025.

Chinese state media took a different angle. Xinhua described the tariff as "further evidence of American economic isolationism" and noted that China supplies roughly 13% of pharmaceutical intermediates used in US drug production. The commentary suggested the tariff would "accelerate China's own pharmaceutical self-sufficiency."

Hospital systems and pharmacy chains warned of near-term disruption. The American Hospital Association said in a statement that its members "cannot absorb a 20% cost increase on pharmaceuticals without passing costs to patients or reducing services." CVS Health said it was "evaluating the impact" on its supply agreements.

The tariff arrives during a war that has already disrupted global supply chains. The Hormuz Strait closure has slowed pharmaceutical shipments from Indian manufacturers that rely on Middle Eastern shipping routes. Adding tariffs to supply constraints creates what Goldman Sachs analysts called "a compounding pressure on drug availability" in a note to clients.

Congressional reaction fell largely along party lines. Senate Finance Committee Chair Mike Crapo said the tariffs "send a clear signal that America's health security depends on domestic manufacturing." Sen. Ron Wyden called them "a tax on sick people dressed up as trade policy."

The order includes a 180-day review period during which the US Trade Representative will assess manufacturer compliance plans. Companies that submit "credible onshoring timelines" may receive tariff deferrals, though the criteria for credibility were not defined.

Patients on specialty drugs face the most immediate risk. Biologics — complex drugs for conditions like cancer, rheumatoid arthritis, and multiple sclerosis — are overwhelmingly manufactured at a small number of overseas facilities. Rebuilding that manufacturing capacity in the United States would take five to seven years, according to estimates from the Biotechnology Innovation Organization.

The next scheduled tariff increase is January 1, 2028.